aalto1 untyped-item.component.html
Quality of anticoagulation and outcomes after mechanical aortic valve replacement in patients with atrial fibrillation : a nationwide cohort study
Loading...
Access rights
openAccess
CC BY
CC BY
Creative Commons license
Except where otherwised noted, this item's license is described as openAccess
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Unless otherwise stated, all rights belong to the author. You may download, display and print this publication for Your own personal use. Commercial use is prohibited.
Date
Major/Subject
Mcode
Degree programme
Language
en
Pages
11
Series
European Heart Journal : Quality of Care and Clinical Outcomes, Volume 11, issue 5, pp. 654-664
Abstract
Aims: Mechanical aortic valve replacement (AVR) remains the primary treatment for younger patients with severe aortic valve disease. However, limited information is available regarding the quality of the required lifelong vitamin K antagonist (VKA) therapy, atrial fibrillation (AF), and their relationship with adverse events after AVR. This study assessed the quality of VKA therapy prior to bleeding and ischaemic events following mechanical AVR in patients with AF. Methods and results: The registry-based Finnish AntiCoagulation in Atrial Fibrillation study combining data from several Finnish healthcare registers covers all patients diagnosed with AF during 2007–18 in Finland. This analysis included patients undergoing mechanical AVR before or after the AF diagnosis. A total of 1086 patients with mechanical AVR and AF either before (41.2%) or after (58.8%) the operation were identified. Cumulative incidence estimates at 10 years after AVR were 27.9% for significant bleeding, 5.8% for intracranial haemorrhage, 12.8% for ischaemic stroke, and 7.2% for myocardial infarction. Time in therapeutic range (TTR) < 80% with international normalized ratio (INR) target 2.0–3.5 was associated with higher bleeding occurrence [adjusted hazard ratio (aHR) 1.97, 1.39–2.79, P < 0.001]. Time in therapeutic range with INR target ≥2.0 was associated with higher stroke occurrence (aHR/standard deviation 1.22, 1.01–1.46, P = 0.035). Mortality was high (28.9%/10 years), and TTR <80% was associated with higher mortality (aHR 2.74, 2.00–3.76, P < 0.001). Conclusion: Adverse events, particularly major bleeding, are common in patients with AF following mechanical AVR, and mortality is high. Suboptimal TTR appears to predict bleeding episodes, ischaemic stroke, and death, and it could be useful in high-risk patient identification and targeting of preventive strategies.
Description
Publisher Copyright: © The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.
Other note
Citation
Lehto, J, Björn, R, Halminen, O, Linna, M, Haukka, J, Putaala, J, Mustonen, P, Kinnunen, J, Hartikainen, J, Airaksinen, J K E, Kiviniemi, T O & Lehto, M 2025, 'Quality of anticoagulation and outcomes after mechanical aortic valve replacement in patients with atrial fibrillation : a nationwide cohort study', European Heart Journal : Quality of Care and Clinical Outcomes, vol. 11, no. 5, pp. 654-664. https://doi.org/10.1093/ehjqcco/qcaf028